Literature DB >> 3541122

Mycobacterial infections in AIDS patients, with an emphasis on the Mycobacterium avium complex.

L S Young, C B Inderlied, O G Berlin, M S Gottlieb.   

Abstract

Serious infections caused by the Mycobacterium avium complex (MAC) have been increasingly recognized over the last three decades. However, the epidemic of the acquired immunodeficiency syndrome (AIDS) has increased interest in these infections. Disseminated mycobacterial disease is common in patients with AIDS, and MAC is the predominant bacterial isolate. Indeed, at UCLA Medical Center, MAC organisms are now the predominant isolates in both AIDS- and non-AIDS-associated mycobacterial disease. MAC lung infections have been difficult to treat. Complex regimens employing four to six drugs are not clearly effective and are usually associated with considerable toxicity. Treatment of MAC infections in patients with AIDS has been particularly frustrating, and evidence that treatment can either eradicate disease or prolong life is limited. MAC organisms are invariably resistant to traditional antituberculosis medications. We have examined a variety of other compounds, and our findings, based on both in vitro and animal-model studies, have identified drugs which, when used in combination, are potentially of therapeutic utility.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3541122     DOI: 10.1093/clinids/8.6.1024

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  89 in total

1.  Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages.

Authors:  S Majumdar; D Flasher; D S Friend; P Nassos; D Yajko; W K Hadley; N Düzgüneş
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

2.  In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins.

Authors:  H Saito; H Tomioka; K Sato; M Emori; T Yamane; K Yamashita; K Hosoe; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.

Authors:  S Naik; R Ruck
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

4.  Environmental factors affecting the occurrence of mycobacteria in brook waters.

Authors:  E K Iivanainen; P J Martikainen; P K Väänänen; M L Katila
Journal:  Appl Environ Microbiol       Date:  1993-02       Impact factor: 4.792

5.  Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanine.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 6.  Agents of newly recognized or infrequently encountered mycobacterial diseases.

Authors:  L G Wayne; H A Sramek
Journal:  Clin Microbiol Rev       Date:  1992-01       Impact factor: 26.132

7.  Detection of Mycobacterium tuberculosis by PCR amplification with pan-Mycobacterium primers and hybridization to an M. tuberculosis-specific probe.

Authors:  V J Tevere; P L Hewitt; A Dare; P Hocknell; A Keen; J P Spadoro; K K Young
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

8.  Induction and expression of protective T cells during Mycobacterium avium infections in mice.

Authors:  R Appelberg; J Pedrosa
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

9.  In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis.

Authors:  R T Mehta; A Keyhani; T J McQueen; B Rosenbaum; K V Rolston; J J Tarrand
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

10.  Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits.

Authors:  M Emori; H Saito; K Sato; H Tomioka; T Setogawa; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.